[Tislelizumab in second line treatment for advanced oesophageal squamous cell carcinoma after previous treatment with platinum-based therapy]

Jeanne Duval; Aziz Zaanan

doi:10.1016/j.bulcan.2024.03.006

[Tislelizumab in second line treatment for advanced oesophageal squamous cell carcinoma after previous treatment with platinum-based therapy]

Bull Cancer. 2024 Jul-Aug;111(7-8):629-631. doi: 10.1016/j.bulcan.2024.03.006. Epub 2024 May 20.

[Article in French]

Authors

Jeanne Duval¹, Aziz Zaanan²

Affiliations

¹ Département d'oncologie digestive, hôpital Saint-Antoine, université Paris Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: [email protected].
² Department of Digestive Oncology, Georges-Pompidou European Hospital, Assistance publique-Hôpitaux de Paris, université Paris Cité, 20, rue Leblanc, 75015 Paris cedex, France. Electronic address: [email protected].

PMID: 38772846
DOI: 10.1016/j.bulcan.2024.03.006

No abstract available

Keywords: Advanced; Anti-PD1; Avancé; Carcinome épidermoïde; Deuxième ligne; Esophagus; Immunotherapy; Immunothérapie; Second-line; Squamous cell carcinoma; Œsophage.

Publication types

Letter
Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Esophageal Neoplasms* / drug therapy
Esophageal Neoplasms* / pathology
Esophageal Squamous Cell Carcinoma* / drug therapy
Humans
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
tislelizumab
Antineoplastic Agents, Immunological